Atsena Therapeutics

#Atsena Therapeutics #Clinical research #Gene therapy #Ocular diseases

Navigating academia and industry to deliver ocular gene therapies

Dr Shannon E Boye, Co-Founder and Chief Scientific Officer of Atsena Therapeutics, writes about the company's journey to the clinic for a challenging ocular gene therapy target.   I have worked for nearly 20 years across academia and the biopharmaceutical industry to develop gene therapies for inherited retinal diseases. I met Sanford Boye, my other half in life and in science, in the lab. If you name… Read More

#Exclusive Content

#Atsena Therapeutics #Clinical trial #FDA #Gene therapy #Ophthalmology

Atsena expedites gene therapy for X-linked retinoschisis

The US Food and Drug Administration (FDA) has agreed to the expansion of Atsena Therapeutics’ ongoing Phase I/II LIGHTHOUSE study of ATSN-201 into a continuous Phase I/II/III trial in the treatment of X-linked retinoschisis (XLRS).   “This regulatory milestone marks another significant step toward delivering a potentially first- and best-in-class gene… Read More

#News #Regulatory